Skip to main content
. 2012 Apr 3;17(4):513–524. doi: 10.1634/theoncologist.2012-0003

Figure 1.

Figure 1.

Incidence of key bevacizumab-related adverse events in selected phase III randomized clinical trials.

Abbreviations: ATE, arterial thromboembolism; BV, bevacizumab; GIP, gastrointestinal perforation; HTN, hypertension; MAX, Mitomycin Avastin® Xeloda.